EP Patent

EP4493539A1 — Treatment of cutaneous neurofibromas with mirdametinib

Assigned to SpringWorks Therapeutics Inc · Expires 2025-01-22 · 1y expired

What this patent protects

The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4493539A1
Jurisdiction
EP
Classification
—
Expires
2025-01-22
Drug substance claim
No
Drug product claim
No
Assignee
SpringWorks Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.